SEOVF OTC
Credit Risk of going bust: higher than 80% of companies Debt: 6.2% of company value Bonds: none of note held by US funds details ▾
Total debt $1.8M against a stock market value of $28.1M.
Distance to default 2.59 (Merton model): prices to 2026-10-26, balance sheet 2026-07-31, debt counted $1.8M (short-term plus half of long-term), stock volatility 98.9%; Altman Z'' -1884.44. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Mississauga, ON L5A 4H2
CA
Sernova Corp. is a Canadian firm, established in 1998 and headquartered in London, that specializes in advanced regenerative medicine therapeutics and is currently in its clinical development phase. The company's primary objective is to innovate and bring to market novel treatments, with a core focus on its unique "Cell Pouch" system. This sophisticated medical device is engineered to create a highly vascularized environment within the body, enabling the successful implantation and integration of therapeutic cells. Once integrated, these cells are designed to continuously release vital proteins or hormones, providing a long-term approach to managing debilitating chronic conditions like diabetes, hemophilia, and thyroid disease. Accompanying the Cell Pouch are related technologies that involve specialized therapeutic cells and methods to shield them from the body's immune response. Sernova actively collaborates with AgeX Therapeutics, Inc. to develop immune-protected therapeutic cells and maintains a research partnership with the University of Miami to further refine its Cell Pouch cell therapy platform.
